Repligen: Forecast Upgrade and BioLife Deal Fuel Biopharma Stock
Reading Time: 3 minutes
Strong quarterly results: Repligen significantly exceeds market estimates for revenue and profit and experiences a rapid increase in orders. Forecast upgrade & acquisition: The raised annual outlook and the $1.5 billion acquisition of BioLife massively boost the stock. Long-term perspective: The company solidifies its absolute market leadership in the rapidly growing biopharma segment. Following a surprisingly strong quarterly report and a significant forecast upgrade, institutional investors are buying into Repligen's stock with extreme...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
